학술논문

Regression of left ventricular hypertrophy after tafamidis therapy in a patient with transthyretin amyloidosis variant
Document Type
Journal Article
Source
The Journal of Medical Investigation. 2022, 69(3.4):320
Subject
cardiomyopathy
hereditary amyloidosis
hypertrophic hepertrophy
Language
English
ISSN
1343-1420
1349-6867
Abstract
Transthyretin amyloidosis (ATTR) variant is a life-threatening hereditary disease predominantly affecting the peripheral nervous system and heart. Tafamidis, which prevents the deposition of amyloid by stabilizing transthyretin, is available for the treatment of neuropathy and cardiomyopathy of ATTR. However, whether tafamidis could eliminate established amyloid deposits and improve cardiac function remains unknown. We reported a case of regression of left ventricular hypertrophy after tafamidis therapy in a patient with an ATTR variant. J. Med. Invest. 69 : 320-322, August, 2022